Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab combination platform study in previously treated unresectable or metastatic melanoma
NL-OMON55514Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of spartalizumab, ieramilimab, capmatinib, canakinumab and ribociclib in melanoma (4 arms), sponsored by Novartis. Primary endpoint: Confirmed objective response rate. Started Feb 2019; status: completed.
02
Drugs
spartalizumabieramilimabcapmatinibcanakinumabribociclib
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON55514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55514.